Biliary Tract Neoplasms: all 492 studies

Page 1 of 5. Open to participants first (191), then studies with results posted, then the rest; newest registration first within each.

• Single-arm, Multicenter, Open-label Phase II Study of Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract CancerEnrolling by invitationNCT07890311Phase 2
• A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerRecruitingNCT07854600Phase 2
• A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract CancerRecruitingNCT07850791Phase 2
• Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract TumorsNot yet recruitingNCT07841873Phase 2
• Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract CancerRecruitingNCT07831993Phase 2
• Bile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract CancerNot yet recruitingNCT07830628
• Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.Not yet recruitingNCT07829874Phase 2
• SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid TumorsRecruitingNCT07812805Phase 1
• Suprapapillary Versus Transpapillary Plastic Stents for Unresectable Malignant Hilar Biliary ObstructionNot yet recruitingNCT07811791Not applicable
• A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsRecruitingNCT07807956Phase 1
• Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract CancerRecruitingNCT07797816Phase 2
• Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingNCT07793253Phase 2
• Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive CholangiocarcinomaRecruitingNCT07786766Phase 2
• Tucatinib Continuation StudyNot yet recruitingNCT07768358Phase 4
• YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic MalignanciesRecruitingNCT07763301Phase 1
• Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingNCT07745296Phase 3
• IKS04 Regimen in Advanced Solid Tumors That Express CA242Not yet recruitingNCT07738939Phase 1
• QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract CancerRecruitingNCT07733115Phase 2
• A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.Not yet recruitingNCT07729033Phase 2
• Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct TumorsRecruitingNCT07726446Phase 2
• Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingNCT07710885Phase 3
• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2
• Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract CancerNot yet recruitingNCT07701122Phase 2
• A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.RecruitingNCT07679399Phase 2
• Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsRecruitingNCT07673861Not applicable
• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingNCT07670273Phase 2
• An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract MalignanciesRecruitingNCT07668453Phase 2
• Study of Occupational Risk Factors for Biliary and Pancreatic CancersNot yet recruitingNCT07668024
• Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase IINot yet recruitingNCT07649980Phase 2
• Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract CancerRecruitingNCT07641036Phase 1/2
• Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract CancerNot yet recruitingNCT07638501Phase 2
• Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract CancerRecruitingNCT07636798Phase 1/2
• Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid TumorNot yet recruitingNCT07631884Phase 2
• A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT07619235Phase 4
• Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract CancerRecruitingNCT07614061Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationsRecruitingNCT07610798Phase 1/2
• Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing PancreatectomyNot yet recruitingNCT07608458Not applicable
• A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingNCT07606599Phase 3
• Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract MalignanciesNot yet recruitingNCT07599995Phase 2
• To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingNCT07594964Phase 1
• A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingNCT07582315Phase 3
• Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract CancerRecruitingNCT07569679Phase 2
• Adebrelimab Plus S-1 for Resected CholangiocarcinomaNot yet recruitingNCT07561775Phase 2
• Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive JaundiceNot yet recruitingNCT07532759Not applicable
• Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruitingNCT07530445Phase 2
• A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCERNot yet recruitingNCT07515950
• Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard TherapyRecruitingNCT07506057Phase 2
• HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract CancerRecruitingNCT07466238Not applicable
• A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationRecruitingNCT07458347Phase 1
• TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World CohortNot yet recruitingNCT07454486
• A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract CancerRecruitingNCT07450976Phase 2
• Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract CancersNot yet recruitingNCT07437287Phase 2/3
• Cosiporfin Sodium for Injection Photodynamic TherapyRecruitingNCT07398339Phase 2
• Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersRecruitingNCT07337850
• Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsRecruitingNCT07334119Phase 1
• An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingNCT07282262Phase 2
• A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07269158Phase 1/2
• Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerRecruitingNCT07267078Phase 2
• A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerRecruitingNCT07265674Phase 3
• Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic CholangiocarcinomaRecruitingNCT07235007Not applicable
• A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)RecruitingNCT07221253Phase 3
• In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersRecruitingNCT07206355
• A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid MalignanciesRecruitingNCT07197554Phase 1
• Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract CancerNot yet recruitingNCT07169916Not applicable
• Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)RecruitingNCT07161869
• The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic CancerNot yet recruitingNCT07160283Phase 2
• Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2
• Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract CancerRecruitingNCT07159204Phase 2
• MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract CancerRecruitingNCT07156058Not applicable
• ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerRecruitingNCT07151118
• Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCRecruitingNCT07142226
• A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract CancerRecruitingNCT07135544Phase 2
• Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract CancerNot yet recruitingNCT07129018Phase 2
• The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant TumorsNot yet recruitingNCT07109167Phase 2
• Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract CancerRecruitingNCT07107750Phase 1
• A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination RegimenNot yet recruitingNCT07099794Phase 2
• Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer PatientsRecruitingNCT07062263Phase 3
• AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)RecruitingNCT07038343Phase 1/2
• Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaRecruitingNCT07030140Phase 2
• Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract CancerRecruitingNCT07025174Phase 2
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingNCT07020221Phase 1/2
• Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract CancerNot yet recruitingNCT07003815Phase 2
• Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract MalignanciesNot yet recruitingNCT06993025Phase 2
• GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）RecruitingNCT06988592
• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid TumorsRecruitingNCT06975410Phase 1/2
• A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/2
• A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerRecruitingNCT06938321Phase 1/2
• CDH17 CAR-T Therapy in Advanced Malignant Solid TumorsRecruitingNCT06937567Early Phase 1
• Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)Not yet recruitingNCT06919848Phase 2
• The Study of Association of Helicobacter Infections in Biliary Tract CancersRecruitingNCT06909188
• Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk CholangiocarcinomaNot yet recruitingNCT06903273Phase 2
• Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract CancerRecruitingNCT06893380
• Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational StudyRecruitingNCT06849193
• Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid TumorsRecruitingNCT06819215Phase 1/2
• Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary CancerNot yet recruitingNCT06818773Phase 4
• A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyRecruitingNCT06793709
• Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingNCT06789848Phase 2
• A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruitingNCT06778031Phase 2
• A Phase 1 Study of LNCB74 in Advanced Solid TumorsRecruitingNCT06774963Phase 1
• A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 2

← Biliary Tract Neoplasms overview